



We want to offer pet parents a treatment option for hemangiosarcoma. We know that this cancer is particularly overwhelming and we are here to support you and your pet in every way possible.

Why Participate in This Clinical Trial?

Hemangiosarcoma is one of the many cancers shared by dogs and people, yet there is an unmet need for new therapies to improve their condition. In the US, there are currently only seven approved medications to treat cancer in dogs (three of which are FDA-approved and four are USDA) and none specifically approved to treat hemangiosarcoma.

Pet parents are faced with limited treatment options, high cost of care and a poor survival prognosis. Sadly, as a consequence, pets with hemangiosarcoma of the spleen are often put to sleep.

The One Health Company's clinical trials offer a new option at no cost to pet parents. Extensive safety and efficacy studies are always performed before any therapy is used in a One Health Company trial. We will never test a medication on your pet that has not already proven safe and effective in other species of animals (and sometimes people). Every patient enrolled in The One Health Company Hemangiosarcoma Clinical Trial receives chemotherapy (never a placebo) and remains at home with their family so that they are comfortable and enjoy quality time together. Participation for each pet is expected to be six months. However, pet parents will be free to remove their pet from a clinical trial at any point.

The well-being of your pet is of utmost importance to us.



A large, stylized green paw print graphic is positioned on the left side of the page, extending from the top to the bottom. It consists of four distinct pads of varying sizes and shapes, all rendered in a solid light green color.

Information on the Investigational Agent

The chemotherapeutic medication being used in this study is an Investigational Agent that is FDA-approved for the treatment of human patients with a subtype of soft tissue sarcoma.

In human studies, the Investigational Agent has demonstrated significant anti-tumor effects including tumor growth inhibition, regression, remission and increased life span for the patient. Safety studies have previously been conducted to guide the current doses and regimen for this proposed trial.

The Investigational Agent has the potential to control many types of cancers, including canine hemangiosarcoma. It is currently used in advanced liposarcoma in humans and may be beneficial for treating dogs with hemangiosarcoma of the spleen due to the similarities between canine hemangiosarcoma and other sarcomas.

In addition to its primary anticancer effects, the Investigational Agent may also have effects on the remaining tumors to be less aggressive and therefore less likely to metastasize.

Trial Details and Specifics

If your pet dog has recently been diagnosed with hemangiosarcoma of the spleen, he or she may be eligible to participate in The One Health Company Canine Hemangiosarcoma Clinical Trial. During the enrollment process we prioritize your pet's best interests and choose pets who we believe will benefit the most from this therapy.

Prior to receiving chemotherapy, each dog will receive a comprehensive physical examination to guarantee his or her ability to tolerate the medication. Pets will receive the Investigational Agent intravenously on day 1 and day 8 of the treatment, and will then have a fourteen-day recovery period. This cycle may be administered three times. If pets are responding well to the chemotherapy protocol, a second round will be administered at a higher, tolerated dose. If adverse effects are encountered then dose delays and adjustments during therapy will be made. If your pet does not tolerate the therapy, the study will be terminated to ensure the safety of your pet.

A veterinarian or veterinary technician will always administer the chemotherapy. Any individual administering or handling chemotherapy agents have appropriate up-to-date training and clearance from the site's Environmental Health and Safety Institute or Occupational Safety and Health Administration Department.

It is very important to know that pet parents may voluntarily withdraw their dog from the clinical trial at any point and that the trial's investigator may also stop a pet's participation if there are any clinical concerns. A pet's participation is expected to last approximately six months.

For more information, speak to your veterinarian or contact Dr. Dara Kraitchman and Dr. Rebecca Krimins at cigat@jhmi.edu or Monday-Friday at (410) 502-7325. Please leave a message and someone will return your call.

Trial Location:

Center for Image-Guided Animal Therapy
The Johns Hopkins University
Baltimore, MD 21287

Enrollment Starts:

April 2017

Reference

David M. Vail & E. Gregory Macewen (2000) Spontaneously Occurring Tumors of Companion Animals as Models for Human Cancer, *Cancer Investigation*, 18:8, 781-792

